Contract facts
FederalVACCINES INCLUDING BUT NOT LIMITED TO: HEPATITIS A, HEPATITIS B, COMBINED HEPATITIS A AND B, MMRMEASLES, MUMPS, RUBELLA, TDTETANUS, DIPHTHERIA, TDAPTETANUS, DIPHTHERIA AND PERTUSSIS, MENINGITIS, RABIES, POLIO, TYPHOID INJECTABLE AND ORAL, YELLOW FEV is a federal award for Division 1200 held by Glaxosmithkline LLC. Estimated value —.
VACCINES INCLUDING BUT NOT LIMITED TO: HEPATITIS A, HEPATITIS B, COMBINED HEPATITIS A AND B, MMRMEASLES, MUMPS, RUBELLA, TDTETANUS, DIPHTHERIA, TDAPTETANUS, DIPHTHERIA AND PERTUSSIS, MENINGITIS, RABIES, POLIO, TYPHOID INJECTABLE AND ORAL, YELLOW FEV
Incumbent footprint
Public recordGlaxosmithkline LLC — $3.0B obligated across 194 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).
Related awards
Same incumbentQuery this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 15F06722A0000187?
15F06722A0000187 (Vaccines including BUT NOT limited to) is a Division 1200 award with an estimated value of —, currently held by Glaxosmithkline LLC. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
Which office awarded 15F06722A0000187?
Division 1200 awarded 15F06722A0000187 to Glaxosmithkline LLC.
Who is the incumbent on 15F06722A0000187?
Glaxosmithkline LLC is the incumbent with $3.0B across 194 related awards in SCOUT’s public footprint.
When does Glaxosmithkline LLC’s 15F06722A0000187 come up for recompete?
SCOUT tracks a period-of-performance end of an unstated date. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.